C12N 2760/16133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/16133 (Use of viral protein as therapeutic agent other than vaccine) appears on 15 US grants and 34 published applications in this corpus.
Search patents in C12N- Granted patents
- 15
- Published applications
- 34
- Assignees
- 19
- Inventors
- 54
- Latest grant
- 1 Nov 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 3 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 2 | 1 |
| 2015 | 1 | 3 |
| 2016 | 4 | 3 |
| 2017 | 3 | 1 |
| 2018 | 1 | 3 |
| 2019 | 1 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 2 | 1 |
| 2023 | 0 | 3 |
| 2024 | 0 | 6 |
| 2025 | 0 | 2 |
By publication year.
Recent patents
- Use of immune suppressive domains as medicaments1 Nov 2022US 11,484,567 B2Aarhus Universitet
- Recombinant influenza virus-like particles (VLPS) produced in transgenic plants6 Sep 2022US 11,434,497 B2Medicago Inc.
- High titer recombinant influenza viruses with enhanced replication in vero cells20 Oct 2020US 10,808,229 B2Wisconsin Alumni Research Foundation (WARF)
- Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin29 Jan 2019US 10,190,132 B2Medicago Inc.
- High titer recombinant influenza viruses with enhanced replication in vero cells28 Aug 2018US 10,059,925 B2Wisconsin Alumni Research Foundation (WARF)
- Deoptimized influenza viruses and methods of treating cancer23 Oct 2025US 2025/0325650 A1Codagenix Inc.
- Simultaneous detection of antigens and antigen specific antibodies in a guinea pig model system27 Mar 2025US 2025/0102520 A1Vanderbilt University
- Multivalent viral particles21 Nov 2024US 2024/0382580 A1Cornell University
- Universal Influenza Vaccine and Methods of Use14 Nov 2024US 2024/0374708 A1
- Self-amplifying messenger rna12 Sep 2024US 2024/0301006 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- High titer recombinant influenza viruses with enhanced replication in vero cells26US 9,109,013 B2Wisconsin Alumni Research Foundation · 2015
- High titer recombinant influenza viruses with enhanced replication in vero cells23US 10,059,925 B2Wisconsin Alumni Research Foundation (WARF) · 2018
- High titer recombinant influenza viruses with enhanced replication in vero cells17US 10,808,229 B2Wisconsin Alumni Research Foundation (WARF) · 2020
- Engineered polypeptide agents for targeted broad spectrum influenza neutralization11US 8,637,456 B2Massachusetts Institute of Technology · 2014
- Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines7US 8,802,110 B2Massachusetts Institute of Technology · 2014